CELL-BOUND COMPLEMENT ACTIVATION PRODUCTS AS DIAGNOSTIC BIOMARKERS FOR PRE-LUPUS
Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as ex...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French German |
Published |
10.03.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus. |
---|---|
Bibliography: | Application Number: EP20200184446 |